PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 26 filers reported holding PHARVARIS N V in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $78,125,802 | +37.8% | 3,743,450 | 0.0% | 43.39% | +55.7% |
| Q2 2023 | $56,675,833 | +116.7% | 3,743,450 | +15.3% | 27.86% | +105.3% |
| Q1 2023 | $26,153,989 | -28.4% | 3,246,926 | 0.0% | 13.57% | -13.0% |
| Q4 2022 | $36,527,918 | +46.7% | 3,246,926 | 0.0% | 15.60% | +94.8% |
| Q3 2022 | $24,904,000 | -65.3% | 3,246,926 | 0.0% | 8.01% | -58.5% |
| Q2 2022 | $71,757,000 | +21.3% | 3,246,926 | -0.5% | 19.32% | +16.8% |
| Q1 2022 | $59,155,000 | +26.0% | 3,261,926 | 0.0% | 16.55% | +71.4% |
| Q4 2021 | $46,939,000 | -18.8% | 3,261,926 | 0.0% | 9.66% | +13.4% |
| Q3 2021 | $57,834,000 | -4.8% | 3,261,926 | 0.0% | 8.52% | +3.7% |
| Q2 2021 | $60,770,000 | -33.4% | 3,261,926 | 0.0% | 8.21% | -24.9% |
| Q1 2021 | $91,269,000 | – | 3,261,926 | – | 10.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,246,926 | $26,153,989 | 13.57% |
| venBio Partners LLC | 2,278,575 | $18,353,922 | 10.17% |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $25,620 | 3.20% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 559,387 | $4,505,862 | 1.86% |
| 5AM Venture Management, LLC | 587,600 | $4,733,118 | 1.21% |
| Sio Capital Management, LLC | 228,385 | $1,839,641 | 0.91% |
| Novo Holdings A/S | 1,329,325 | $10,714,360 | 0.71% |
| Cormorant Asset Management, LP | 816,460 | $6,577 | 0.43% |
| Soleus Capital Management, L.P. | 336,900 | $2,713,730 | 0.28% |
| GENERAL ATLANTIC, L.P. | 2,420,155 | $19,494,349 | 0.23% |